Smarter Cancer Care
Exact Sciences brings the promise of precision medicine
to life with Oncotype IQ, a full suite of genomic tests.

Landmark RxPONDER Trial Results

Presented at the 2020 SABCS

Learn more about the data from the RxPONDER trial and how it successfully defines the benefit of chemotherapy in early-stage, node-positive breast cancer patients with Oncotype DX Breast Recurrence Score® results of 0 to 25.

Exact Sciences' Response to COVID-19

A Letter from our CEO, Kevin Conroy

What Is the Test
The Oncotype DX test reveals the underlying tumour biology to help guide treatment decisions.
Learn More
Prognostic vs. predictive

Only a truly predictive test can identify the right treatment for the right patient
Learn why it matters
TAILORx

TAILORx results eliminate uncertainty around intermediate scores and show that most patients do not benefit from chemotherapy
Get the results
Standard of Care

Only the Oncotype DX Breast Recurrence Score test is incorporated in the four major international guidelines and recommended by two major EU health technology assessment (HTA) bodies.
See the guidelines

Contact Us

 Get in Touch
Copyright © 2004- Genomic Health, Inc. All Rights Reserved.
In the US and certain other jurisdictions, Genomic Health, Oncotype DX, Oncotype IQ, Recurrence Score, Oncotype DX Breast Recurrence Score, Oncotype DX Colon Recurrence Score, Oncotype DX Genomic Prostate Score, and Oncotype DX AR-V7 Nucleus Detect are registered trademarks, and "Making cancer care smarter" and GPS are pending registered trademarks, of Genomic Health, Inc.
Making cancer care smarter.™
X

This site uses cookies. These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is used only to improve the website. By visiting this website, you agree that we can place these types of cookies on your device.